COVID-19 Preparedness: Early Insights from the 23rd Commissioner of the U.S. Food and Drug Administration, Dr. Scott Gottlieb

March 14, 2020

The goal of epidemiology is to identify factors related to the occurrence of disease, to enable development of a rational basis for prevention. Dr. Gottlieb shares insights on the virus and its epidemiology; what we know now and what we will have to adapt to. Dr. Gottlieb is the 23rd commissioner of the US Food and Drug Administration. He now serves on the board of Pfizer and Illumina, and is resident fellow at the American Enterprise Institute and a partner at the venture capital firm, New Enterprise Associates. Prior to being the FDA commissioner, Dr. Gottlieb served as FDA’s deputy commissioner for medical and scientific affairs and before that, as a senior advisor to the administrator of the centers for Medicare and Medicaid services where he helped advance the agency’s coverage policies related to new medical technology. Dr. Gottlieb is widely published in leading medical journals and periodicals and has held editorial positions at British Medical Journal and the Journal of the American Medical Association.